SUMMARY Serum thyroid stimulating hormone and thyroxine concentrations were monitored in 42 infants who had been treated for congenital hypothyroidism. Serum 
Screening programmes for congenital hypothyroidism were first reported in 19751 2 We now report plasma thyroid stimulating hormone and thyroxine concentrations after replacement treatment in children detected in the congenital hypothyroid screening programme in the South West region of England between 1981 and 1986. We have correlated these concentrations with the dose of L-thyroxine/kg body weight in an attempt to calculate optimal dosage regimens.
Patients and methods
The infants screened were those born in the South West region of England from 1981 to 1986 . Capillary blood samples for the measurement of thyroid stimulating hormone were collected in duplicate on filter paper when babies were 7 days old and sent to the regional screening laboratory at Southmead Hospital, Bristol. Thyroid stimulating hormone was measured by an immunoradiometric assay (sensitivity 8 mU/l, interassay variation 12%). A blood spot thyroid stimulating hormone concentration of <25 mU/l was regarded as normal; a concentration of >80 mU/l was considered abnormal and infants were referred to a local paediatrician for clinical assessment and further biochemical investigations. Repeat blood spots were requested on neonates whose blood spot thyroid stimulating hormone concentrations were in the range 25 to 80 mU/l. If the blood spot thyroid stimulating hormone was >25 mU/l on repeat analysis the infant was referred to a local paediatrician for further investigations. The Medical Research Council definition of congenital hypothyroidism was adopted. This comprises a plasma or serum total thyroxine concentration by quantitative analysis of less than 65 nmol/l, or a plasma or serum thyroid stimulating hormone concentration by quantitative analysis of more than 10 mU/l.
Treatment with L-thyroxine and the children's progress were supervised by the local paediatricians. Treatment was monitored by the filter paper capil-1368 lary blood assay for thyroid stimulating hormone. If the blood spot thyroid stimulating hormone concentrations were higher than the detection limit of the assay (8 mU/l), paediatricians were advised to check the plasma or serum concentrations of thyroxine and thyroid stimulating hormone.
We identified through the screening laboratory all children with raised serum or plasma thyroid stimulating hormone concentrations (that is, >10 mU/l) and extracted clinical and biochemical data and treatment regimens from their hospital case notes. The data were analysed by comparing those with raised plasma thyroid stimulating hormone concentrations with those with normal concentrations.
Comparison of the serum thyroxine concentrations and doses of L-thyroxine between the two groups was by the Mann-Whitney test and Student's t test, respectively. Statistical analysis was done of the pooled results and of the results at different ages.
Results
The population of the south west of England is roughly three million, and the annual birth rate about 37 000, and 185 723 infants (99% of all newborn babies) were screened between 1981 and 1986. The recall rate for a repeat sample was 0. 11% .
Forty two infants (16 boys and 26 girls) had 300 1-0 0 primary congenital hypothyroidism according to the Medical Research Council definition. The incidence is 1:4400. Seven other infants (five boys, two girls) had raised plasma thyroid stimulating hormone concentrations and total thyroxine concentrations within the normal range (all were more than 100 nmol/1). Three have subsequently become hypothyroid (unpublished observations).
The mean age at diagnosis was 13-8 days (range 9-18), that at starting treatment was 16 days (range 9-38), and that at the time of study was 31-5 months (range 6-63).
After treatment the serum thyroid stimulating hormone concentrations were raised in 22 of the infants (52%) between 2 and 4 months, in 16 (38%) between 5 and 11 months, in 14 (33%) between 12 and 18 months, and in eight (19%) between 2 and 4 years. Serum thyroxine concentrations were never below the normal range for age throughout the study period but were significantly lower in the infants with raised thyroid stimulating hormone concentrations (p <0-0001) (fig 1 and table) . Only one infant had persistently raised thyroid stimulating hormone concentrations in the presence of serum thyroxine concentrations in the upper part of the normal range and a satisfactory thyroxine dose/kg body weight (described as 'delayed maturation' in the figures). In all other instances thyroid Mulating hormone measured on 34 occasions and all but one were within the lower range of normal. Thyroid stimulating hormone was normally reduced in four infants when their serum thyroxine concentrations rose into ly reduced when the upper range of normal. Schultz et al suggested appropriately in-that the hypothalamic/pituitary threshold for reduction ofthyroid stimulating hormone is unusually idy weight varied high in infancy and their data confirm the need for study period but serum thyroxine to be kept in the upper range of Lrly infancy. The normal.
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A number of reports have confirmed that the dose of thyroxine/kg body weight is high in infancy and decreases through childhood into adult life.'3 14 15 These recommended doses range from 8-10 jig/kg in infancy to 5-6 jig/kg in early childhood, and fall to 3-4 jg/kg in later childhood. Our data confirm these doses.
Some authors believe that delayed maturation of the hypothalamic/pituitary/thyroid axis is the reason for the persistently raised thyroid stimulating hormone concentrations in early childhood in children treated for congenital hypothyroidism. We believe that this is rare, and the term should be limited to those infants in whom appropriate doses of Lthyroxine are given, in whom serum thyroxine is persistently in the upper range of normal, and in whom the thyroid stimulating hormone remains raised. Only one infant in our study fulfilled these criteria.
Our data confirm that a raised thyroid stimulating hormone concentration after treatment for congenital hypothyroidism generally denotes undertreatment. A similar conclusion was reached by Frost and Parkin in a study in older children, 22% of whom had raised thyroid stimulating hormone concentrations and were receiving inappropriate treatment. 16 There is some evidence that infants apparently being adequately treated for congenital hypothyroidism do not perform as well as controls.58 Whether this is due to events before or after birth is unknown, but it does reinforce the need for careful surveillance of the children's treatment. We recommend that the infants are reviewed every two months during the first year of life when body weight is increasing rapidly. Then if the serum thyroid stimulating hormone is raised the serum thyroxine must be checked and the dose of Lthyroxine increased to maintain it in the upper range of normal. If this is done it will prevent undertreatment and the inappropriate diagnosis of delayed maturation of the hypothalamic/pituitary/ thyroid axis. 
